PRAGUE, Czech Republic and LONDON, UK I March 03, 2025 I SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today presented the ...

Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs ...

Akari Therapeutics Plc (Nasdaq: AKTX), a biotechnology company developing next-generation precision bi-functional antibody ...

Frazier Life Sciences has launched Callio Therapeutics with $187 million in series A funds and a HER2-targeted dual-payload ...

Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients ...

More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a ...

Oqory’s planned reverse merger with fellow antibody-drug conjugate (ADC) company Vincerx Pharma has fallen apart at the last ...

Pharmaceutical scientists at the National University of Singapore (NUS) have developed a novel chemical reaction that enables the precise functionalization of peptides and proteins.

Approval would expand the use of Enhertu to breast cancer patients with nearly undetectable HER2 levels in their tumors.

Pharmaceutical scientists at the National University of Singapore (NUS) have developed a novel chemical reaction that enables ...

The FDA approved the investigational new drug application for a phase 1 trial of ADCE-T02 in advanced solid tumors.

RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and OS Therapies Inc. (NYSE American:OSTX) on the RedChip Small Stocks, Big Money™ show, a sponsored ...